blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3194397

EP3194397 - 2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD) [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  21.02.2020
Database last updated on 14.09.2024
FormerGrant of patent is intended
Status updated on  21.05.2019
FormerRequest for examination was made
Status updated on  03.05.2019
FormerGrant of patent is intended
Status updated on  09.01.2019
FormerRequest for examination was made
Status updated on  15.12.2018
FormerGrant of patent is intended
Status updated on  12.08.2018
FormerRequest for examination was made
Status updated on  23.06.2017
FormerThe international publication has been made
Status updated on  25.11.2016
Most recent event   Tooltip21.02.2020Application deemed to be withdrawnpublished on 25.03.2020  [2020/13]
Applicant(s)For all designated states
Chronos Therapeutics Limited
41 Cornmarket Street
Oxford OX1 3HA / GB
[2017/30]
Inventor(s)01 / SEMERARO, Teresa
c/o Aptuit (Verona) S.r.l.
Via Alessandro Fleming 4
I-37135 Verona / IT
02 / TARSI, Luca
c/o Aptuit (Verona) S.r.l.
Via Alessandro Fleming 4
I-37135 Verona / IT
03 / MICHELI, Fabrizio
c/o Aptuit (Verona) S.r.l.
Via Alessandro Fleming 4
I-37135 Verona / IT
04 / LUKER, Tim
32 Flamingo Court
Nottingham NG7 1GJ / GB
05 / CREMONESI, Susanna
c/o Aptuit (Verona) S.r.l.
Via Alessandro Fleming 4
I-37135 Verona / IT
 [2017/30]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[N/P]
Former [2017/30]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Application number, filing date15774985.414.09.2015
[2017/30]
WO2015IB57029
Priority number, dateGB2014001634616.09.2014         Original published format: GB 201416346
[2017/30]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2016042451
Date:24.03.2016
Language:EN
[2016/12]
Type: A1 Application with search report 
No.:EP3194397
Date:26.07.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 24.03.2016 takes the place of the publication of the European patent application.
[2017/30]
Search report(s)International search report - published on:EP24.03.2016
ClassificationIPC:C07D471/10, C07D491/20, C07D498/10, C07D513/10, A61K31/438, A61K31/499, A61K31/537, A61K31/547, A61P15/10, A61P25/22, A61P25/30, A61P25/04, A61P25/20, A61P3/04
[2017/30]
CPC:
C07D471/10 (EP,CN,US); A61P15/00 (EP); A61P15/10 (EP);
A61P25/00 (EP); A61P25/02 (EP); A61P25/04 (EP);
A61P25/14 (EP); A61P25/18 (EP); A61P25/20 (EP);
A61P25/22 (EP); A61P25/24 (EP); A61P25/28 (EP);
A61P25/30 (EP); A61P25/34 (EP); A61P3/04 (EP);
C07D491/20 (EP,CN,US); C07D498/10 (EP,CN,US); C07D513/10 (EP,CN,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/30]
TitleGerman:2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ON-DERIVATE UND VERWANDTE VERBINDUNGEN ALS INHIBITOREN DES MENSCHLICHEN DOPAMIN-ACTIV-TRANSPORTER (DAT) PROTEINS ZUR BEHANDLUNG VON Z.B. AUFMERKSAMKEITSSTÖRUNGEN[2018/35]
English:2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)[2017/30]
French:DÉRIVÉS DE 2-[BIS(4-FLUOROPHÉNYL)MÉTHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE ET COMPOSÉS SIMILAIRES EN TANT QU'INHIBITEURS DU PROTEIN HUMAINE DU TRANSPORT ACTIF DE LA DOPAMINE (TAD) POUR LE TRAITEMENT DU TROUBLE DU DÉFICIT DE L'ATTENTION[2018/35]
Former [2017/30]2-[BIS(4-FLUORPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ON-DERIVATE UND VERWANDTE VERBINDUNGEN ALS HEMMER DES MENSCHLICHEN DOPAMIN-AKTIV-TRANSPORTER (DAT)-PROTEINS ZUR BEHANDLUNG VON Z.B. AUFMERKSAMKEITSSTÖRUNGEN (ADD)
Former [2017/30]DÉRIVÉS DE 2-[BIS(4-FLUOROPHÉNYL)MÉTHYL]-2,7-DIAZASPIRO[4.5]DÉCAN-10-ONE ET COMPOSÉS APPARENTÉS EN TANT QU'INHIBITEURS DE LA PROTÉINE TRANSPORTEUSE ACTIVE DE DOPAMINE (DAT) HUMAINE POUR LE TRAITEMENT PAR EX. D'UN TROUBLE DE DÉFICIT DE L'ATTENTION (TDA)
Entry into regional phase12.04.2017National basic fee paid 
12.04.2017Designation fee(s) paid 
12.04.2017Examination fee paid 
Examination procedure12.04.2017Examination requested  [2017/30]
12.04.2017Date on which the examining division has become responsible
14.11.2017Amendment by applicant (claims and/or description)
13.08.2018Communication of intention to grant the patent
13.12.2018Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
10.01.2019Communication of intention to grant the patent
01.05.2019Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
22.05.2019Communication of intention to grant the patent
02.10.2019Application deemed to be withdrawn, date of legal effect  [2020/13]
11.11.2019Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time  [2020/13]
Fees paidRenewal fee
12.09.2017Renewal fee patent year 03
11.09.2018Renewal fee patent year 04
Penalty fee
Additional fee for renewal fee
30.09.201905   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[X]US5698567  (GUILLONNEAU CLAUDE [FR], et al) [X] 1-13 * examples 6-27, 31-42 *;
 [A]US6835371  (ELMALEH DAVID R [US], et al) [A] 1-16 * example 26 * * claims 1,2,8,10 *
 [X]  - FRITCH, PAUL C.; KRAJEWSKI, JEFFREY, "Design, syntheses, and SAR of 2,8-diazaspiro[4.5]decanones as T-type calcium channel antagonists", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (2010), vol. 20, no. 22, doi:10.1016/j.bmcl.2010.09.098, ISSN 0960-894X, pages 6375 - 6378, XP002750980 [X] 1-15 * page 6375, column r, paragraph 1st * * page 6376; right-hand column; table 1; compounds 11-21; scheme 2 * * page 6377; left-hand column; scheme 3; compound 21 *

DOI:   http://dx.doi.org/10.1016/j.bmcl.2010.09.098
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.